Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

Micron surge is bullish for these other stocks, says Bank of America

View original at finance.yahoo.com
Micron surge is bullish for these other stocks, says Bank of America I started investing in the 1990s and joined Wall Street on the sell side in 1997…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • KLA is a best-in-breed stock and is the one stock in his coverage that he has never downgraded from a 'buy' rating

    80% confidence
  • Micron's sales and profit will jump to $18.7 billion and $8.42 per share in the upcoming quarter

    80% confidence
  • Etch/dep (AMAT/LRCX) could expand to 42% of share, up 3% since 2023, with NAND and HBM contributing to gains for all three companies

    80% confidence
  • This WFE upcycle is more powerful and durable than previous ones, suggesting continued semicap outperformance in CY26

    80% confidence
  • Semicaps will outperform in CY26 as upstream beneficiaries of capacity expansions and tech upgrades to support multi-year AI infra demand, with upside in C2H'26 and CY27 as visibility into capex plans and fab ramp timelines improves

    80% confidence
  • Semicap equipment will see 10%/14% YoY growth in CY26/27E towards $131bn/$150bn driven by fab upgrades to support high-bandwidth memory, higher layer count NAND, leading-edge logic and advanced packaging

    80% confidence
  • Process control will gain 100 bps of share to 13% of WFE in 2026

    80% confidence
  • To address tight supply-demand conditions extending beyond 2026, capital spending in fiscal 2026 will be approximately $20 billion weighted to the second half of the fiscal year

    80% confidence
  • An evolving supercycle could be a strong tailwind for semiconductor equipment and manufacturing stocks, including those tied to memory capital expenditures

    80% confidence
  • 2026 will feature another ~30% growth towards the first $1tn for semiconductor sales, supported by nearly double-digit YoY wafer fab equipment (WFE) sales growth

    80% confidence
  • FCF margins at AMAT, LRCX, and KLAC could reach 20% to 30% through 2028

    80% confidence
  • Training is significantly and increasingly compute-intensive, and compute needs are accelerating rapidly, particularly as more models move into production

    80% confidence
  • Semicap trading at a premium to historical multiples, but there is potential for continued EPS upgrades given consensus models' bottom-up sales growth (6-8% annual) below our top-down WFE (10%+) forecast

    80% confidence
  • Reasoning models answering challenging queries could require over 100 times more compute compared to single-shot inference

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Micron surge is bullish for these other stocks, says Bank of America — Source | Via News | ViaNews EU